Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies
|
|
- Byron Shields
- 6 years ago
- Views:
Transcription
1 doi: /j x REVIEW ARTICLE Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies N. Rosencher, 1 M.-P. Bonnet 1 and D. I. Sessler 2 1 Staff Anaesthesiologist, Department of Anaesthesiology and Intensive Care, Groupe Hospitalier Cochin Port Royal, Assistance Publique Hôpitaux de Paris, Université René Descartes (Paris 5), Paris, France 2 Department of OUTCOMES RESEARCH, The Cleveland Clinic, Cleveland, Ohio; and OUTCOMES RESEARCH Institute and Department of Anaesthesiology, University of Louisville, Louisville, KY, USA Summary We propose recommendations to reduce the risk of haemorrhagic events associated with regional anaesthesia in patients treated with newer anticoagulants after orthopaedic surgery. The risk benefit ratio should be individualised for each patient according to the type and dose of anticoagulant, the type of regional anaesthesia and patient risk factors. Neuraxial anaesthetic management strategy can be based on the pharmacokinetic properties of specific anticoagulants, including the time required to reach maximal concentration, half-life, and dose regimen. Central neuraxial blocks should not be performed and epidural catheters should not be removed until at least two half-lives after the last injection of anticoagulant, the half-life depending on renal function. After removing a catheter or after a haemorrhagic puncture, the timing of the next anticoagulant injection should be based on the time required for an anticoagulant dose to reach maximum activity. Vigilance remains paramount during the initial days after removal of a neuraxial catheter.... Correspondence to: Dr Nadia Rosencher nadia.rosencher@cch.aphp.fr Accepted: 27 May 2007 Peri-operative thrombotic complications are common; for example, roughly half of all patients not given thromboprophylaxis will develop venographically evident deepvein thrombosis after major orthopaedic surgery, and 10% of those who do, will suffer a pulmonary embolism [1]. It is thus usual to provide antithrombotic drugs to patients undergoing major orthopaedic surgery [1]. Neuraxial anaesthesia, especially spinal and epidural anaesthesia, is often used for hip and knee arthroplasty, as well as for open reduction and internal fixation of hip fractures. Neuraxial anaesthesia is associated with a small but distinct risk of epidural haematoma (1 haematoma per cases) [2]; however, the risk is increased 15-fold by concomitant use of anticoagulant therapy when appropriate precautions are not taken [3]. Haematomas can also be problematic after deep lumbar plexus blocks. Epidural haematomas can be devastating complications, with paralysis occurring even after surgical decompression. Whatever the anticoagulant agent, the balance between the benefits (prevention of venous thromboembolism, a major cause of peri-operative morbidity and mortality) and risks (major bleeding and epidural haematoma) is the central consideration. This balance not only depends on the pharmacology of each agent, but also on the dosage, timing of administration, the type of surgery and patient characteristics. Because the incidence of epidural haematomas is so low, it is difficult to study enough patients to determine the specific risk associated with each new antithrombotic agent. For similar reasons, it is impossible to determine accurately how best to minimise the risk of spinal haematomas while maintaining effective prevention of thrombosis. Available guidelines thus aim to minimise the risk of spinal haematoma by restricting catheter or needle insertion and removal to periods when the concentration of anticoagulant is low. Risk can be further reduced by delaying anticoagulation until after surgery an approach 1154 Journal compilation Ó 2007 The Association of Anaesthetists of Great Britain and Ireland
2 N. Rosencher et al. Æ Anaesthesia and antithrombotic agents which apparently does not increase the risk of venous thrombosis [4, 5]. This brief review will focus on the management of anticoagulant drugs in patients requiring regional anaesthesia. An electronic search was performed using three electronic databases: Pubmed Ò (MEDLINE Index Medicus), the Cochrane Central Register of Randomised Controlled Trials published by the Cochrane Library, and Embase. The medical subject heading terms used for the search were neuraxial anaesthesia, antithrombotic agents and orthopaedic surgery. The electronic research was completed by a manual search in the reference lists of original published articles, reviews and correspondences. We will discuss the relative risks and benefits of regional and general anaesthesia, consider factors that increase the risk of epidural haematomas, and recommend strategies for using neuraxial anaesthesia in patients who are given some of the newer anticoagulants. These recommendations will generally be based on the pharmacology of each anticoagulant. Overall, anaesthetist should take into consideration the pharmacokinetics of any particular anticoagulants and be alert to the signs and symptoms of epidural haematoma, which include back pain, sensory changes, progressive paralysis and incontinence. Suspicion should prompt diagnostic imaging and, when appropriate, surgical intervention. General vs regional anaesthesia for orthopaedic surgery Initial studies suggested that the risk of mortality and morbidity (including venous thromboembolism) was less with neuraxial anaesthesia than with general anaesthesia [6 8]. However, one meta-analysis and two large studies failed to confirm this benefit [9 11]. More recently, two meta-analyses by Rodgers et al. [12] and Urwin et al. [13] identified a small decrease of the incidence of deep-vein thrombosis after regional anaesthesia compared with general anaesthesia. A critical point, though, is that both recent meta-analysis included older trials (more than twothirds were performed before 1990), when thromboprophylaxis was not used routinely for hip fracture surgery. In most recent studies, using newer anticoagulants and risk-adjusted dosing, the risk of deep-vein thrombosis incidence was not reduced by neuraxial anaesthesia [14]. Available data thus suggest that neuraxial anaesthesia decreased the rate of deep-vein thrombosis before the widespread use of effective prophylactic anticoagulation, but no longer does in patients given appropriate antithrombotic treatment with newer agents [14, 15]. Neuraxial anaesthesia also fails to reduce blood loss or transfusion requirements [16]. Nonetheless, neuraxial anaesthesia is often chosen for elective orthopaedic surgery in preference to general anaesthesia because it provides better pain control and facilitates rehabilitation [17]. Risk of deep haematoma The interval between initiation of low molecular weight heparin (LMWH, e.g. enoxaparin) therapy and neurological dysfunction as a sign of neuraxial haematoma ranges from 15 h to 3 days, but neuraxial haematoma is uncommon immediately after surgery [18, 19]. One explanation for this important lag between puncture or catheter removal and haematoma is the accumulation of anticoagulant after 3 days in older patients with poor creatinine clearance, as an example of patient factors that interplay to influence drug effect. Neurological examinations should thus continue for up to 3 postoperative days as complete neurological recovery is more likely if surgical decompression occurs within 8 h after onset of paralysis [18]. The actual source of the bleeding (arterial or venous) remains controversial and it is difficult to understand why several of the haematomas associated with LMWH involved less blood than the volume routinely injected when performing a therapeutic blood patch [19], a routine treatment for postspinal headache. Procedure-related risk factors for spinal haematoma include haemorrhagic puncture [20], multiple punctures, catheter insertion and traumatic catheter removal. Formation of spinal haematomas is also facilitated when haemostasis is impaired, for example by the concomitant administration of medications such as non-steroidal antiinflammatory drugs (NSAIDs) or other antiplatelet agents. Additional risk factors for spinal haematoma include older age (> 75 years), female gender, and the presence of spinal column abnormalities [2, 19, 21]. The overall risk of epidural haematoma is estimated to be less than 1 in epidural injections and 1 in spinal injections [2, 22]. However, this risk increases to 1 in and 1 in , respectively, in patients who had experienced a traumatic spinal tap or were already receiving heparin or acetylsalicylic acid [2]. A recent study by Moen et al. [23] of patients found that the overall incidence of epidural haematomas was around 1 in patients, but that the incidence of haematomas increased to 1 in 3600 when analysis was restricted to epidural anaesthesia with a catheter for total knee replacement in women older than 70 years of age. These results are in accordance with those reported in a recent retrospective review [24]. Indeed, three neuraxial haematomas were detected in 8000 neuraxial anaesthetics, always associated with Journal compilation Ó 2007 The Association of Anaesthetists of Great Britain and Ireland 1155
3 N. Rosencher et al. Æ Anaesthesia and antithrombotic agents Anaesthesia, 2007, 62, pages epidural catheter, 2 days after insertion of an epidural catheter. Schroeder estimated that the incidence of spinal haematoma in patients undergoing neuraxial blockade in combination with LMWH in the United States was 1 in spinal and 1 in 3100 epidural injections [3]. It is thus apparent that risk increases substantially in elderly women in whom an epidural catheter is inserted with concomitant anticoagulant therapy and bloody puncture [20]. General strategies for use of neuraxial anaesthesia in anticoagulated patients It would be difficult to evaluate the risk of spinal haematoma based on data from phase II and III clinical trials of new agents. For one thing, patients with important risk factors for bleeding are typically not included; for another, few if any trials include a sufficient number of patients to quantify this rare event. Current recommendations Numerous anaesthesia societies, including the American Society of Regional Anesthesia [21] and European groups [25 27], have proposed guidelines to improve the safety of neuraxial techniques performed in patients treated with heparins (unfractionated or low-molecular-weight heparin) or oral anticoagulants (e.g. vitamin K antagonists). These practical recommendations were designed to optimise both the safety and the efficacy of prophylaxis in the presence of neuraxial anaesthesia. Interestingly, the recommendations for prevention of haemorrhagic complications associated with neuraxial anaesthesia in patients given LMWH differ from country-to-country, and across continents. Indeed, in most European countries, the recommendations are that placement or removal of a spinal or epidural needle catheter should be delayed at least 12 h after the last anticoagulant dose, but the recommendation is to delay 20 h in France and 10 h in the United States. Subsequent administration of LMWH is not recommended until 4 h after catheter removal in Europe, but is considered acceptable after only 2 h in the USA. In France, LMWH therapy is not initiated until 6 h after surgery in patients having neuraxial anaesthesia [28]. Considerations for managing epidural catheters in the setting of anticoagulation Table 1 Pharmacokinetics of anticoagulants in patients with normal creatinine clearance. Medication Half-life; h T max ;h UFH IV [38] 1 2 Immediately UFH SC [38] LMWH SC [38] Fondaparinux SC [32] Dabigatran (oral) [34] Rivaroxaban (oral) [23,36,39] UFH, unfractionated heparin; LMWH, low molecular weight heparin; T max, time to reach maximal plasma concentration or maximal anticoagulant activity; SC, subcutaneous; iv, intravenous. The recommendations we propose are drug-specific and are based on the pharmacokinetics of each agent; specifically, the half-life and time to reach maximum plasma concentration or maximum antithrombotic activity (T max, Table 1). There are two parts to our recommendations: the first is how long to delay before removing neuraxial catheters and the second is when to restart anticoagulation. These recommendations are relevant to doses used for thrombosis prophylaxis, rather than therapeutic anticoagulation. Catheter removal We suggest delaying removal of a neuraxial catheter until at least two half-lives have elapsed for the specific anticoagulant involved (Figs 1 and 2). After two halflives, only 25% of the medication remains active. After this interval, elimination slows considerably so waiting longer only slightly decreases the residual drug concentration. An obvious limitation to this strategy is the slight residual anticoagulant activity, but it seems a reasonable compromise between the risk of haemorrhagic complications and the risk of thrombosis. T max Two half lives Delay before next dose = T haem T max Removal catheter T haem = time for haemostasis Time Figure 1 The half-life of the anticoagulant in this example is 17 h and T max is 1 h (as for fondaparinux). Catheter removal should thus be delayed at least 36 h and, because safety time should be at least 8 h, the next injection should at least 7 h after withdrawing the catheter (i.e. 8 h T max ) Journal compilation Ó 2007 The Association of Anaesthetists of Great Britain and Ireland
4 N. Rosencher et al. Æ Anaesthesia and antithrombotic agents T max Two half lives Removal of catheter Delay before next dose = T haem T max T max T haem = Time for haemostasis Time Figure 2 The half-life of the anticoagulant in this example is 4 5 h and T max is 4 h (as for LMWH). Catheter removal should thus be delayed at least 10 h and, because safety time should be at least 8 h, the next injection should be at least 4 h after withdrawing the catheter (i.e. 8 h T max ). The elimination half-life of LMWH increases by around 40% in patients with severe renal impairment (creatinine clearance = 30 ml.min )1 ) [29]. The dose of LMWH should thus be reduced, perhaps by a factor of two, in patients with severe renal disease. However, little if any adjustment seems necessary in patients with less impaired renal function. At this point, though, no specific recommendation has been validated in patients with mild renal impairment. A similar recommendation can be made for fondaparinux, and would apply to new antithrombotic drugs that depend on renal elimination. Restarting anticoagulation It takes about 8 h for an initial platelet plug to solidify into a stable clot that will remain intact after administration of additional anticoagulant medications [30]. This delay of 8 h is in accordance with Turpie s meta-analysis on fondaparinux [14]. Indeed, there is a relationship between the risk of major bleeding and the first dose of anticoagulant: If the drug is started within the 6 h after surgery, it increases major bleeding without improving efficacy. The abnormally higher risk of major bleeding disappears 6 h after the end of surgery, i.e. 8 h after neuraxial puncture. It would thus seem prudent to delay restarting anticoagulant medications until a stable clot has been established. However, this does not imply waiting 8 h in each patient, because the onset time (T max ) of most anticoagulants is substantial. Instead, we recommend waiting for 8 h minus T max. This strategy means that a total of 8 h will have elapsed before the peak of anticoagulation is re-established. In practice, the longer the T max, the shorter the delay. For instance, if the T max is 4 h (as it is for LMWH), the safety delay would be 4 h; but if the T max is only 1 h (as it is for unfractionated heparin), the safety delay should be at least 7 h (Figs 1 and 2). The obvious limitation of this approach is that T max defines the time of peak activity after anticoagulant administration. However, anticoagulation obviously begins at some earlier time and gradually increases until maximum effect is reached. Thus, waiting at least 8 h minus T max does not assure extremely low anticoagulant levels for a full 7 h. On the other hand, it seems a reasonable compromise between the risk of haemorrhagic complications and the risk of thrombosis. Other considerations There is considerable individual variability in baseline coagulation and in the response to anticoagulants. Obviously, the time to get complete haemostasis decreases with low platelet counts in patients with severe anaemia, and in those given dextran or antiplatelet agents. Retroperitoneal haematoma resulting from posterior lumbar plexus blocks may cause femoral nerve compression and can even lead to life-threatening bleeding [31]. The risk factors for haemorrhagic complications associated with plexus blocks appear to be similar to those associated with spinal haematomas. Consequently, a similar approach to anticoagulation might be used in patients having deep plexus blocks, including posterior lumbar plexus and sciatic parasacral approaches. Management of regional anaesthesia in patients given selected, newer anticoagulants Fondaparinux Recently, subcutaneous fondaparinux sodium, a synthetic pentasaccharide based on the active pentasaccharide sequence of heparin, was licensed for the prevention and treatment of venous thromboembolism. Fondaparinux is a synthetic indirect anti-xa inhibitor and acts as an anticoagulant by binding antithrombin. Fondaparinux catalyses factor Xa inhibition by antithrombin, but has no effect on the rate of thrombin inactivation. Fondaparinux has a high bioavailability (nearly 100%) and a rapid onset of action (25 min) after subcutaneous administration. It reaches peak concentrations within 1 2 h. Terminal plasma half-life is 17 h in healthy patients, but is prolonged in patients with moderate renal impairment [32]. Fondaparinux received marketing approval for thromboprophylaxis after orthopaedic surgery in Europe and the USA in It is usually given once daily, at a subcutaneous dose of 2.5 mg, starting 6 12 h after surgical closure. The manufacturer suggests that fondaparinux be started between 6 and 8 h after the end of surgery. An indwelling Journal compilation Ó 2007 The Association of Anaesthetists of Great Britain and Ireland 1157
5 N. Rosencher et al. Æ Anaesthesia and antithrombotic agents Anaesthesia, 2007, 62, pages epidural catheter should not be removed until 36 h (at least two half-lives) after the previous dose, and the next dose should not be given until 12 h after catheter removal. This delay is higher than suggested by the pharmacokinetics of the drug, but is more convenient. Thus, there needs to be a window of 48 h between two injections of fondaparinux, which is achieved by skipping one injection. This strategy was used successfully in a recent multicentre study (EXPERT) [33] in which 5704 patients were treated with 2.5 mg.day )1 of subcutaneous fondaparinux for 4 weeks after major orthopaedic surgery. A neuraxial or deep peripheral indwelling catheter was inserted in 1630 patients (29%). Overall, the rate of symptomatic venous thromboembolism was 1.0% and was similar in the patients with and without a catheter. Dabigatran etexilate Dabigatran etexilate is a new oral pro-drug of the direct thrombin inhibitor dabigatran, which is being developed by Boehringer Ingelheim [34, 35]. It is a low-molecularweight, reversible thrombin inhibitor that binds to thrombin with a high affinity and specificity. Phase III trials with dabigatran etexilate are completed and it seems likely to be clinically available soon. The half-life of dabigatran etexilate ranges from 14 to 17 h after multiple dose administration. After oral administration, plasma concentration increases rapidly, reaching a maximum after 2 4 h. In trials so far published, dabigatran etexilate was tested only postoperatively and was given orally once daily at 150 or 200 mg, starting with a half dose 1 4 h after the end of surgery. In a recent study of patients having total knee replacement, efficacy and safety (including liver function) of dabigatran etexilate did not differ significantly from subcutaneous LMWH in a non-inferiority trial [35]; it thus seems likely that the drug will soon be approved for routine clinical use because oral dosing is more convenient. As the pharmacokinetic properties of this drug are established, we can speculate about its management with regional anaesthesia, which should be similar to that suggested for fondaparinux. Indeed, with dabigatran an indwelling epidural catheter should not be removed before 36 h (at least two half-lives) after the previous dose, and the next dose should not be given any sooner than 12 h after catheter removal. There thus needs to be a window of 48 h between two doses. In practice, this can be achieved by skipping one dose. Rivaroxaban Rivaroxaban (BAY ) is a potent, selective, oral factor Xa inhibitor, developed by Bayer Health Care. It belongs to a new class of oxazolidinone-based, active-site directed, factor Xa inhibitors. Factor Xa is located at the common intersection of the extrinsic and the intrinsic pathways for thrombin formation. Selective inhibition of factor Xa by rivaroxaban is expected to terminate the amplified burst of thrombin generation created during the hypercoagulable state that occurs after total knee replacement. This may result in better efficacy in preventing thrombus formation and therefore produce a better safety profile than other anticoagulants. Phase III trials with rivaroxaban are completed and it seems likely that the drug will soon be approved for routine clinical use. As a prophylactic treatment, rivaroxaban should be administered once daily at a dose of 10 mg, starting 6 8 h after the end of surgery. The halflife ranges from 7 to 9 h after multiple dose administration, but can be higher in elderly patients. After an oral administration, a rapid increase in rivaroxaban plasma concentration is observed, reaching a maximum at about 2 4 h [36]. In all the orthopaedic trials, rivaroxaban was tested only postoperatively. Because the pharmacokinetic properties of this drug are known [36], we can speculate about its management in conjunction with regional anaesthesia, which should be similar to that proposed for LMWH in Europe. Indeed with rivaroxaban, an indwelling epidural catheter should be removed at least 20 h (at least two half-lives) after the previous dose, and the next dose should be given 6 h after catheter removal. New oral anticoagulant agents in early development in major orthopaedic surgery Agents in the early stages of development (i.e. ongoing phase II studies) include several Xa inhibitors (Lilly , YM150, DU-176b, apixaban [BMS ]). Glaxo- Smith-Kline, Sanofi-Aventis, and Hoffman La Roche also have phase II studies planned. There is also an orally active glycosaminoglycan enhancer (odiparcil [SB ]), which indirectly enhances thrombin inhibition via heparin cofactor II and has completed Phase II development. However, recommendations for use of these very new agents in conjunction with regional anaesthesia will need to wait until their pharmacokinetics will be better defined. Conclusion In summary, risk factors for haematoma related to regional anaesthesia analgesia vary according to patient characteristics (age, weight, creatinine clearance and concomitant medications), the difficulties associated with the needle puncture, and the pharmacokinetic properties of the anticoagulant. Our recommendations are based on the pharmacokinetics of specific anticoagulants. Basically, we suggest allowing at least two half-lives to pass before catheter removal, and taking into account the time 1158 Journal compilation Ó 2007 The Association of Anaesthetists of Great Britain and Ireland
6 N. Rosencher et al. Æ Anaesthesia and antithrombotic agents required to establish a stable clot and to reach maximum activity (T max ) before restarting anticoagulation. In patients who receive chronic anticoagulant treatment, complete reversal of anticoagulation is probably not advisable due to the risk of postoperative thromboembolic complications. But when patients are not routinely anticoagulated, it appears preferable to avoid pre-operative anticoagulation before regional anaesthesia as this approach reduces the risk of anaesthesia-related haemorrhagic complications without increasing the risk of postoperative thrombotic complications. Patients should be observed for signs and symptoms of neurological impairment for 3 days after catheter removal. Clinical suspicion should prompt immediate diagnostic imaging, usually a magnetic resonance scan, and intervention as required. The overall strategy we suggest the following. Consider the risk benefit ratio of neuraxial anaesthesia for each patient. In general, outcomes appear comparable with general and neuraxial anaesthesia [9 11]. Single-shot spinal anaesthesia is safer than insertion of an epidural catheter [21, 25]. Concomitant administration of medications affecting haemostasis such as antiplatelet agents, NSAIDs, or dextran represents an additional risk of peri-operative haemorrhagic complications, including spinal haematoma [21, 25]. Pre-operative initiation of anticoagulation is not required for efficacy. When begun within 2 h of surgery, anticoagulation may increase major bleeding [4, 5]. For example, fondaparinux is effective and not associated with an increased risk of major bleeding if started 8 ± 2 h after surgery; but it increases major bleeding without improving efficacy when the drug is started within 6 h after surgery [14]. For any anticoagulant, indwelling catheters should not be removed until at least two half-lives have passed [37]. The next re-injection depends on the time required to reach maximum concentration (T max ). The time necessary to optimise haemostasis is about 8 h; the minimum safety window can thus be estimated as 8 h ) T max. Monitoring of anti-xa concentrations in the plasma is no longer recommended, because concentrations do not predict the risk of bleeding [21, 25]. The presence of bleeding during needle puncture and catheter placement does not necessitate postponement of surgery. However, anticoagulant therapy should be delayed for 24 h after surgery when bleeding is observed [20, 21, 25]. Acknowledgements Supported by NIH Grant GM (Bethesda, MD), the Gheens Foundation (Louisville, KY), the Joseph Drown Foundation (Los Angeles, CA), and the Commonwealth of Kentucky Research Challenge Trust Fund (Louisville, KY). Hematologists for helping to determine hemostasis time: Dr P Sie, Dr M M Samama, Dr L Drouet. None of the authors has a personal financial interest in the drugs discussed in this review. References 1 Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S 400S. 2 Tryba M, Wedel DJ. Central neuraxial block and low molecular weight heparin (enoxaparine): lessons learned from different dosage regimes in two continents. Acta Anaesthesiologica Scandinavica Supplementum 1997; 111: Schroeder DR. Statistics: detecting a rare adverse drug reaction using spontaneous reports. Regional Anesthesia and Pain Medicine 1998; 23: Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Archives of Internal Medicine 2002; 162: Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Archives of Internal Medicine 1997; 157: Modig J. The role of lumbar epidural anaesthesia as antithrombotic prophylaxis in total hip replacement. Acta Chirurgica Scandinavica 1985; 151: Prins MH, Hirsh J. A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery: a critical review. Thrombosis Haemostasis 1990; 64: Samama CM, Barre J, Clergue F, Samii K. [Benefits of regional anesthesia. Anticoagulant treatment and regional anesthesia]. Annales Françaises d Anesthesie et de Reanimation 1992; 11: Sorenson RM, Pace NL. Anesthetic techniques during surgical repair of femoral neck fractures. A meta-analysis. Anesthesiology 1992; 77: Sutcliffe AJ, Parker M. Mortality after spinal and general anaesthesia for surgical fixation of hip fractures. Anaesthesia 1994; 49: O Hara DA, Duff A, Berlin JA, et al. The effect of anesthetic technique on postoperative outcomes in hip fracture repair. Anesthesiology 2000; 92: Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. British Medical Journal 2000; 321: Urwin SC, Parker MJ, Griffiths R. General versus regional anaesthesia for hip fracture surgery: a meta-analysis of randomized trials. British Journal of Anaesthesia 2000; 84: Journal compilation Ó 2007 The Association of Anaesthetists of Great Britain and Ireland 1159
7 N. Rosencher et al. Æ Anaesthesia and antithrombotic agents Anaesthesia, 2007, 62, pages Turpie AG, Eriksson BI, Bauer KA, Lassen MR. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. Chest 2003; 124: 371S 8S. 15 Rosencher N, Vielpeau C, Emmerich J, Fagnani F, Samama CM. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. Journal of Thrombosis and Haemostasis 2005; 3: Rosencher N, Kerkkamp HE, Macheras G, et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion 2003; 43: Capdevila X, Barthelet Y, Biboulet P, Ryckwaert Y, Rubenovitch J, d Athis F. Effects of perioperative analgesic technique on the surgical outcome and duration of rehabilitation after major knee surgery. Anesthesiology 1999; 91: Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesthesia and Analgesia 1994; 79: Horlocker TT. What s a nice patient like you doing with a complication like this? Diagnosis, prognosis and prevention of spinal hematoma. Canadian Journal of Anaesthesia 2004; 51: Stafford-Smith M. Impaired haemostasis and regional anaesthesia. Canadian Journal of Anaesthesia 1996; 43: R Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Regional Anesthesia and Pain Medicine 2003; 28: Wysowski DK, Talarico L, Bacsanyi J, Botstein P. Spinal and epidural hematoma and low-molecular-weight heparin. New England Journal of Medicine 1998; 338: Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden Anesthesiology 2004; 101: Christie IW, McCabe S. Major complications of epidural analgesia after surgery: results of a six-year survey. Anaesthesia 2007; 62: Tryba M. European practice guidelines: thromboembolism prophylaxis and regional anesthesia. Regional Anesthesia and Pain Medicine 1998; 23: Llau JV, de Andres J, Gomar C, et al. [Drugs that alter hemostasis and regional anesthetic techniques: safety guidelines. Consensus conference]. Revista Espanola de Anestesiologia Y Reanimacion 2001; 48: Anonymous. Belgian guidelines concerning drug induced alteration of coagulation and central neuraxial anesthesia. Acta Anaesthesiologica Belgica 2000; 51: Samama CM, Albaladejo P, Benhamou D, et al. Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines. European Journal of Anaesthesiology 2006; 23: Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thrombosis Research 2002; 105: Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) how does thrombin regulate fibrinolysis? Annals of Medicine 2006; 38: Aveline C, Bonnet F. Delayed retroperitoneal haematoma after failed lumbar plexus block. British Journal of Anaesthesia 2004; 93: Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clinical Pharmacokinetics 2002; 41 (Suppl. 2): Singelyn F, Felicissimo P, Piovella F, Van Aken HK, Rosencher N. Use of neuraxial catheter for anesthesia analgesia in major orthopedic lower limb surgery Patients treated with prophylactic dose of fondaparinux in routine practice (Abstract). Journal of Thrombosis and Haemostasis 2005; 3: Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. Journal of Clinical Pharmacology 2005; 45: Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. Journal of Thrombosis and Haemostasis 2005; 3: Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY an oral, direct Factor Xa inhibitor after multiple dosing in healthy male subjects. European Journal of Clinical Pharmacology 2005; 61: Rosencher N. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations. Anaesthesia 2004; 59: Barrowcliffe TE, Johnson EA, Thomas DP. Low Molecular Weight Heparin. New York: Wiley, Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. British Journal of Surgery 2005; 92: Journal compilation Ó 2007 The Association of Anaesthetists of Great Britain and Ireland
Factor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
More informationJAMES PAGET HEALTHCARE NHS TRUST
CLINICAL GUIDELINE FOR REGIONAL ANAESTHESIA AND THE USE OF LOW MOLECULAR WEIGHT HEPARINS (LMWH) IN THE PERIOPERATIVE PERIOD 1. INTRODUCTION LMWH have been proven to be effective in reducing the risk of
More informationAnesthesia for Total Hip and Knee Arthroplasty
Anesthesia for Total Hip and Knee Arthroplasty Typical approach Describe anesthesia technique Rather Describe issues with THA and TKA How anesthesia can modify Issues Total Hip Total Knee Blood Loss ++
More informationFunding: The ASRA Consensus Conference was funded by unrestricted educational grants from: Pharmacia & Upjohn Company and Aventis Pharmaceuticals
Regional Anesthesia in the Anticoagulated Patient - Defining the Risks Published by the American Society of Regional Anesthesia and Pain Medicine This document has been developed by a Consensus Conference
More informationRegional anaesthesia and antithrombotic drugs
Regional anaesthesia and antithrombotic drugs G Davies FRCA MR Checketts FRCA Matrix references 1A02, 2G01 Key points Vertebral canal haematoma is a rare but potentially devastating complication of central
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationRegional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy
British Journal of Anaesthesia 107 (S1): i96 i106 (2011) doi:10.1093/bja/aer381 Regional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy T. T. Horlocker Department of Anesthesiology,
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationANAESTHESIA FOR LIVER SURGERY
Seminars at 21 Portland Place ANAESTHESIA FOR LIVER SURGERY This seminar is organised in conjunction with the Liver Intensive Care Group of Europe Wednesday 18 th October 2006 Seminars at 21 Portland Place
More informationThere are many advantages of spinal or epidural analgesia/anesthesia
PERIODICUM BIOLOGORUM UDC 57:61 VOL. 115, No 2, 125 130, 2013 CODEN PDBIAD ISSN 0031-5362 Overview Controversies in regional anaesthesia patient on anticoagulant therapy BRANKO TRIPKOVI] Department of
More informationVTE Prevention After Hip or Knee Replacement
This Clinical Resource gives subscribers additional insight related to the Recommendations published in May 2018 ~ Resource #340506 VTE Prevention After Hip or Knee Replacement The American College of
More informationP-RMS: LT/H/PSUR/0004/001
Core Safety Profile Active substance: Dalteparine Pharmaceutical form(s)/strength: Solution for injection, 2500 I.U./0.2ml, 2500 I.U./ml, 5000 I.U./0.2ml, 7500 I.U./0.3ml, 7500 I.U./0.75ml, 10000 I.U./0.4ml,
More informationConsensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture
Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.
More informationThe legally binding text is the original French version. Opinion 15 May 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationThe Critical Thrombosis Period in Major Orthopedic Surgery: When to Start and When to Stop Prophylaxis
The Critical Thrombosis Period in Major Orthopedic Surgery: When to Start and When to Stop Prophylaxis Clinical and Applied Thrombosis/Hemostasis Volume 16 Number 4 July/August 2010 394-405 # 2010 The
More informationincidence of cancer-associated thrombosis (CAT) is further increased by additional risk factors such as chemotherapeutic 2
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the ability of tumour cells to activate the
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More informationANTI COAGULATION AND BLOCKS
ANTI COAGULATION AND BLOCKS Dr S.M. SENTHIL NATHAN, MD, COIMBATORE NEDICAL COLLEGE, COIMBATORE. We now live in a scenario doomed with lot of co-morbidities.one of the important being the cardiovascular
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationNational Institute for Health and Clinical Excellence Health Technology Appraisal
National Institute for Health and Clinical Excellence Health Technology Appraisal Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs Comment
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationNEURAXIAL BLOCKADE AND ANTICOAGULANTS
Soli Deo Gloria NEURAXIAL BLOCKADE AND ANTICOAGULANTS Lecture 4 Developing Countries Regional Anesthesia Lecture Series Daniel D. Moos CRNA, Ed.D. U.S.A. moosd@charter.net Disclaimer Every effort was made
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationAnticoagulation and Neuraxial Anaesthesia
29 May 2009 CONTENTS Anticoagulation and Neuraxial Anaesthesia G Allopi Commentator: R Naidoo Moderator: J Rubin INTRODUCTION... 3 BENEFITS OF NEURAXIAL TECHNIQUES... 4 THE COAGULATION PROCESS... 5 INCIDENCE
More informationPatients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1 ability of tumour cells to activate
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Arixtra 1.5 mg/0.3 ml solution for injection, pre-filled syringe. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled
More informationVenous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials
Winner of the AAHKS Award Venous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials Greg A. Brown, MD, PhD The Journal of Arthroplasty Vol. 24
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More information1. SCOPE of GUIDELINE:
Page 1 of 35 CLINICAL PRACTICE GUIDELINE: Venous Thromboembolism (VTE) Prevention Guideline: Thromboprophylaxis AUTHORIZATION: VP, Medicine Date Approved: May 17, 2012 Date Revised: Vancouver Coastal Health
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationXarelto rivaroxaban Prescriber Guide
Xarelto rivaroxaban Prescriber Guide Patient Alert Card A patient alert card must be provided to each patient who is prescribed Xarelto 2.5 mg, 10 mg, 15 mg or 20 mg and is provided with the product package.
More informationAccepted: 8 April 2009
Open Access Case report Epidural bleeding after ACL reconstruction under regional anaesthesia: a case report Nikolaos T Roidis*, Lazaros A Poultsides, Nikolaos E Gougoulias, Paraskevi D Liakou, Theofilos
More informationVenous thromboembolism - reducing the risk
Venous thromboembolism - reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital NICE guideline Draft for consultation,
More informationPerioperative VTE Prophylaxis
Perioperative VTE Prophylaxis Gregory J. Misky, M.D. Assistant Professor of Medicine University Of Colorado Denver You recommend the following 72 y.o. man admitted for an elective R hip repair. Patient
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationAN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS
The West London Medical Journal 2010 Vol 2 No 4 pp 19-24 AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS Soneji ND Agni NR Acharya MN Anjari
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 15 November 2007 CPMP/EWP/707/98 Rev.1 corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR PROPHYLAXIS
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More information06RC2-Llau. Prophylaxis, diagnosis and treatment of venous thromboembolism. Juan V. Llau. Introduction. Rationale for thromboprophylaxis [1,5] - 1 -
06RC2-Llau Prophylaxis, diagnosis and treatment of venous thromboembolism Juan V. Llau Department of Anaesthesiology and Critical Care Hospital Clínico València, Spain Introduction Pulmonary embolism (PE)
More informationNEW ZEALAND DATASHEET
1. PRODUCT NAME PRADAXA 75 mg hard capsules PRADAXA 110 mg hard capsules PRADAXA 150 mg hard capsules NEW ZEALAND DATASHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION PRADAXA 75 mg hard capsules Each
More informationTransitions of care in anticoagulated patients
Journal of Multidisciplinary Healthcare open access to scientific and medical research Open Access Full Text Article Transitions of care in anticoagulated patients Expert Opinion Franklin Michota Department
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationTRANSPARENCY COMMITTEE OPINION. 18 April 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 April 2007 ARIXTRA 2.5 mg/0.5 ml, solution for injection in prefilled syringe Pack of 2 (CIP: 359 225-4) Pack of
More informationIndividualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationEffect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention
European Heart Journal Supplements (2008) 10 (Supplement C), C8 C13 doi:10.1093/eurheartj/sun004 Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of
More informationCase presentation: A 69-year-old
CLINICIAN UPDATE Prevention of Venous Thromboembolism in Total Knee and Hip Replacement David Warwick, MD, FRCS, FRCS(Orth) Case presentation: A 69-year-old woman had a cemented hip replacement 15 years
More informationVenous thromboembolism: reducing the risk
Issue date: January 2010 Venous thromboembolism: reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital This guideline
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationAppendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS
Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with
More informationGeneral. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations
General Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis
More informationPRODUCT MONOGRAPH. (Enoxaparin sodium solution for injection, manufacturer s standard) 150 mg/ml. 120 mg/0.8 ml
PRODUCT MONOGRAPH Pr LOVENOX (Enoxaparin sodium solution for injection, manufacturer s standard) 100 mg/ml 30 mg/0.3 ml 40 mg/0.4 ml 60 mg/0.6 ml 80 mg/0.8 ml 100 mg/ml 300 mg/3 ml Pr LOVENOX HP (Enoxaparin
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationTITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms
TITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms DATE: 23 August 2011 CONTEXT AND POLICY ISSUES: Thromboembolism occurs when a blood
More informationNew oral anticoagulants and regional anaesthesia
British Journal of Anaesthesia 111 (S1): i96 i113 (2013) doi:10.1093/bja/aet401 REGIONAL ANAESTHESIA New oral anticoagulants and regional anaesthesia H. T. Benzon 1 *, M. J. Avram 1, D. Green 2 and R.
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationPRODUCT MONOGRAPH. fondaparinux sodium injection. 2.5 mg/0.5 ml 5.0 mg/0.4 ml 7.5 mg/0.6 ml 10.0 mg/0.8 ml. ATC Classification: B01AX05
PRODUCT MONOGRAPH Pr ARIXTRA fondaparinux sodium injection 2.5 mg/0.5 ml 5.0 mg/0.4 ml 7.5 mg/0.6 ml 10.0 mg/0.8 ml ATC Classification: B01AX05 Synthetic Antithrombotic Aspen Pharmacare Canada Inc 111
More informationRole and safety of epidural analgesia
Anaesthesia for Liver Resection Surgery The Association of Anaesthetists Seminars 21 Portland Place, London Thursday 15 th December 2005 Role and safety of epidural analgesia Lennart Christiansson MD,
More informationInhixa (Enoxaparin Sodium)
Inhixa (Enoxaparin Sodium) P R E V ENTIS SAFETY D E V I C E P R E V E N T I S I S A N AU TO M AT I C N E E D L E S H I E L D I N G S Y S T E M, W H I C H H A S A C O V E R T H AT E X T E N D S O V E R
More informationEAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY
EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY K.A.O. Tikkinen (Chair), R. Cartwright, M.K. Gould, R. Naspro, G. Novara, P.M. Sandset, P.D. Violette, G.H. Guyatt Introduction Utilising recent
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationTable 4. Efficacy of ARIXTRA Injection in the Prophylaxis of Thromboembolic Events Following Knee Replacement Surgery
Table 4. Efficacy of ARIXTRA Injection in the Prophylaxis of Thromboembolic Events Following Knee Replacement Surgery Endpoint Fondaparinux Sodium 2.5 mg SC 1 Enoxaparin Sodium 30 mg SC every 12 hours
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
More informationIs Oral Rivaroxaban Safe and Effective in the Treatment of Patients with Symptomatic DVT?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 1-1-2013 Is Oral Rivaroxaban Safe and Effective
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationImprinted hypromellose capsules with light blue opaque cap and
AUSTRALIAN PRODUCT INFORMATION PRADAXA dabigatran etexilate 1 NAME OF THE MEDICINE dabigatran etexilate (as dabigatran etexilate mesilate) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION PRADAXA are hard capsules
More informationAntiplatelet and Anticoagulant management for Regional Anesthesia
Antiplatelet and Anticoagulant management for Regional Anesthesia Deborah Richman MBCHB, FFA(SA) Director of Pre-Operative Services Department of Anesthesia Stony Brook MedicineStony Brook, NY SPAQI Immediate
More informationZhongdi Liu, Na Han, Hailin Xu *, Zhongguo Fu, Dianying Zhang, Tianbing Wang and Baoguo Jiang *
Liu et al. BMC Musculoskeletal Disorders (2016) 17:76 DOI 10.1186/s12891-016-0917-y RESEARCH ARTICLE Open Access Incidence of venous thromboembolism and hemorrhage related safety studies of preoperative
More informationRed de Revistas Científicas de América Latina y el Caribe, España y Portugal. Universidad Autónoma del Estado de México
Revista Mexicana de Anestesiología Colegio Mexicano de Anestesiología mariram@prodigy.net.mx, revistacma@mail.medinet.net.mx ISSN (Versión impresa): 0185-1012 MÉXICO 2006 Terese T. Horlocker ANALGESIA
More informationVenous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
More informationBlood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy
Blood Thinner Agent Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Outline: Blood thinner agent definition. anticoagulants drugs. Thrombolytics. Blood thinner agent Therapeutic interference
More informationWARFARIN: PERI OPERATIVE MANAGEMENT
WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationFRAGMIN (dalteparin sodium injection) for Subcutaneous Use Only Initial U.S. Approval: 1994
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FRAGMIN safely and effectively. See full prescribing information for FRAGMIN. FRAGMIN (dalteparin
More informationEdoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354) This document supports the
More informationHIBOR. Bemiparin, INN. Second Generation Low Molecular Weight Heparin
HIBOR Bemiparin, INN Second Generation Low Molecular Weight Heparin 1 Contents 1. Obtention and chemical structure 5 2. Mechanism of action 7 2.1 Anti-thrombotic activity 7 2.2 Release of TFPI 7 2.3 Anti-coagulant
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationNDC NDC NDC NDC NDC NDC
1. 2. 1 3. 2 4. 5. 3 6. 4 7. 5 24 8. 9. 27Gx 1/2 2.5mg 0.5mL NDC 0007-3230-02 2 NDC 0007-3230-11 10 27Gx 1/2 5mg 0.4mL NDC 0007-3232-02 2 NDC 0007-3232-11 10 27Gx 1/2 7.5mg 0.6mL NDC 0007-3234-02 2 NDC
More informationAre guidelines for anticoagulation useful in cancer patients?
Session 3 Striking a Balance Between Bleeding and the Risk of Thrombosis in Cancer Patients Are guidelines for anticoagulation useful in cancer patients? Sebastian Szmit Department of Pulmonary Circulation
More informationDabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting
Rosencher et al. Thrombosis Journal (2016) 14:8 DOI 10.1186/s12959-016-0082-4 ORIGINAL CLINICAL INVESTIGATION Open Access Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement
More informationTechnology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245
Apixaban for the prevention ention of venous thromboembolism after total hip or knee replacement in adults Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245 NICE 2018.
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More information